Form S-8 BRAINSTORM CELL THERAPEU
As filed with the Securities and Exchange Commission on May 20, 2026
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
BRAINSTORM CELL THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
| Delaware | 20-7273918 |
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
1325
Avenue of Americas, 28th Floor, New York, NY, 10019
(Address of Principal Executive Offices, Zip Code)
2014 Stock Incentive Plan
2014 Global Share Option Plan
(Full title of the plan)
Chaim Lebovits
President and Chief Executive Officer
Brainstorm Cell Therapeutics Inc.
1325 Avenue of Americas, 28th Floor
New York, NY 10019
(Name and address of agent for service)
(201) 488-0460
(Telephone number, including area code, of agent for service)
Copies to:
Faith L. Charles, Esq.
Thompson Hine LLP
300 Madison Avenue, 27th Floor
New York, New York 10017
Phone: (212) 908-3905
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ¨ | Accelerated filer | ¨ | |||
| Non-accelerated filer | x | Smaller reporting company | x | |||
| Emerging growth company | ¨ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY NOTE
Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 (this “Registration Statement”) is being filed to register an additional 5,500,000 shares of common stock, par value $0.00005 per share (“Common Stock”), of Brainstorm Cell Therapeutics Inc. (the “Registrant”) reserved under the Registrant’s 2014 Stock Incentive Plan and the 2014 Global Share Option Plan, each as amended through February 26, 2026 (as amended, collectively, the “2014 Plans”). This Registration Statement registers additional securities of the same class as other securities of the Registrant for which the registration statements filed on Form S-8 relating to the 2014 Plans (File No. 333-198391, File No. 333-213714, File No. 333-228981, File No. 333-261598, and File No. 333-288520) of the Registrant are effective. The information contained in the Registrant’s registration statements on Form S-8 relating to the 2014 Plans (File No. 333-198391, File No. 333-213714, File No. 333-228981, File No. 333-261598, and File No. 333-288520) is hereby incorporated by reference pursuant to General Instruction E of Form S-8, except with respect to Item 8. Exhibits thereof.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
| Item 8. | Exhibits. |
The exhibits listed on the Exhibit Index immediately preceding such exhibits are filed as part of this Registration Statement, and the contents of the Exhibit Index are incorporated herein by reference.
EXHIBIT INDEX
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of New York, State of New York, on May 20, 2026.
| BRAINSTORM CELL THERAPEUTICS INC. | ||
| By: | /s/ Chaim Lebovits | |
| Chaim Lebovits | ||
| President and Chief Executive Officer | ||
Each person whose signature appears below constitutes and appoints Chaim Lebovits, Uri Yablonka and Alla Patlis, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Name | Title | Date | ||
|
/s/ Chaim Lebovits Chaim Lebovits |
President and Chief Executive Officer (Principal Executive Officer) |
May 20, 2026 | ||
|
/s/ Alla Patlis Alla Patlis |
Interim Chief Financial Officer (Principal Financial and Accounting Officer) |
May 20, 2026 | ||
|
/s/ Irit Arbel Irit Arbel |
Director | May 20, 2026 | ||
|
/s/ Nir Naor Nir Naor |
Director | May 20, 2026 | ||
|
/s/ Jacob Frenkel Jacob Frenkel |
Director | May 20, 2026 | ||
|
/s/ Anthony Polverino Anthony Polverino |
Director | May 20, 2026 | ||
|
/s/ Uri Yablonka Uri Yablonka |
Director | May 20, 2026 | ||
|
/s/ Menghisteab Bairu Menghisteab Bairu |
Director | May 20, 2026 | ||
|
/s/ Stacy Lindborg Stacy Lindborg |
Director | May 20, 2026 |
ATTACHMENTS / EXHIBITS